Rather than compete against each other, Bristol-Myers Squibb
Bristol's Yervoy, which was recently approved in the U.S., will join forces with Roche's development-stage compound, vemurafenib, in trials to determine whether the two are more effective against skin cancer together than either is individually. Melanoma-related team-ups aren't unique; two years ago, Merck
Bristol's and Roche's drugs aren't competing directly yet, so it's a little hard to tell who will benefit more from the partnership. Presumably, the companies are sharing the clinical trial costs, although they didn't say whether it was a 50/50 split.
However, I'm guessing that Bristol benefits more than Roche. Vemurafenib is a specialized drug designed to treat about half of melanoma patients -- those with a mutation in a protein called BRAF. We'll get more information about the phase 3 trial results at the American Society of Clinical Oncology meeting this weekend, but that won't likely be enough to compare the efficacy of the two drugs. The clinical studies supporting Yervoy didn't look specifically at patients with BRAF mutations, so comparing the overall survival data between the two trials will be fairly meaningless.
Without much to go on, some doctors might pick vemurafenib over Yervoy in the patients with BRAF mutations, simply because it's designed to treat them. Proving that a combination works better could help Bristol gain back those patients.
The advantage for Roche would seem to lie in fighting off competition from other BRAF inhibitors coming up from behind. GlaxoSmithKline
Investors should look for more of these kinds of deals in the future. Like many diseases, cancer is more easily controlled by attacking it from multiple angles.
Like dividend-laden pharmaceutical companies? Here are 13 more high-yielding stocks you can buy today.